Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > Leaving...
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(304)
•••
Comment by beenthereon Dec 01, 2023 8:14pm
125 Views
Post# 35764693

RE:Leaving...

RE:Leaving...

 

I am gradually leaving behind me the trauma of this whole Bioasis  experience ..

WTF!

What trauma are you talking about JD? 

The trauma of all us bag holders losing lots and lots of our hard earned money

and having to put up with Ahole like you for 10 years plus!

And myself losing  over $200 000  with this ......

Please spare us ! You have no idea about trauma  and what it's like!

YOU made money from BTI all these years and We lost money all these years until eventually we lost everything!

Is it our fault you couldn't handle your own personal finances?

And now you want US to feel sorry for you and your " trauma" !  Good one!



I always felt Donald Trump was the king of Narcissist for years now.

Well guess what I think you are a close second!

Somehow I don't believe the title of your post .....

.........Leaving...... ha ha. never !

...PROVE ME WRONG!  ....

....at least I would get something for my $200 000 plus

 

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities